NetworkNewsBreaks Archive - Page 2216 of 2263

WednesdayFeb 01, 2017 1:36 pm

NetworkNewsBreaks – NAPCO Security Technologies, Inc. (NASDAQ: NSSC) Responds to Changing Security Demands, Successfully Grows Top and Bottom Lines

NAPCO Security Technologies (NASDAQ: NSSC), a worldwide manufacturer of various security products, is developing advanced technologies for intrusion, fire, video, wireless, access control and door locking systems for commercial, industrial, institutional, residential and government application. Founded in 1969, the company has a track record of evolution on pace with the changing market for security solutions. Taking advantage of the growing demand for connected home products and alarm systems compatible with 3G cellular networks, NAPCO has launched several new products designed to provide recurring revenue streams and further solidify the company’s position in the broader security market. The company has consistently…

WednesdayFeb 01, 2017 1:34 pm

NetworkNewsBreaks – Westell Technologies, Inc. (NASDAQ: WSTL) Targets Industry Poised for $486M; “Future-proof” PS71090 Slated for Release Q1 2017

Since its founding in 1980, Westell Technologies (NASDAQ: WSTL) has expanded and acclimated to the evolving, high-performance wireless infrastructure solutions industry, offering today’s most technologically advanced in-building wireless, intelligent site management, cell site optimization and outside plant solutions. In November, the company announced the newest member of its in-building wireless coverage solutions portfolio, PS71090 Signal Booster. The “future-proof” solution was designed to meet the strict requirements of the National Fire Alarm Code NFPA 72 standards, as well as the anticipated First Responder Network Authority (FirstNet) requirements. The PS71090 is expected to be generally available in the first quarter of 2017,…

WednesdayFeb 01, 2017 1:31 pm

NetworkNewsBreaks – First Choice Healthcare Solutions, Inc. (FCHS) – Transforming Healthcare Delivery for Doctors and Patients

Quality and distinction matter at First Choice Healthcare Solutions (OTCQB: FCHS). Indeed, the company’s model for success is based on the premise that doctors get to be doctors at its Medical Centers of Excellence and, consequently, patients get excellent “personalized” care. A talented team of healthcare experts and executives are at the helm at First Choice, leveraging a shared vision and tested experience to steer the company’s patient-centric culture, daily operations, smart growth strategies, and long-term value creation. With their guidance, the company is developing its Centers into superior clinical destinations that will offer more significant and collaborative doctor-patient interactions,…

WednesdayFeb 01, 2017 1:29 pm

NetworkNewsBreaks – Atossa Genetics, Inc. (NASDAQ: ATOS) Targets Breast Cancer with Patented Intraductal Microcatheters; Several Patent Applications Pending

Atossa Genetics (NASDAQ: ATOS) is a clinical-stage pharmaceutical company focusing on developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. In 2015, an estimated 231,840 women in the United States were diagnosed with invasive breast cancer, and an estimated 60,000 U.S. women were diagnosed with non-invasive in situ carcinoma. Of those, approximately 40,000 women died from breast cancer. The company’s leading program uses its patented intraductal microcatheters that deliver pharmaceuticals through the breast milk ducts, which may provide a higher concentration of the therapeutic to the target tissue. In March 2016, a phase 2 clinical…

WednesdayFeb 01, 2017 1:26 pm

NetworkNewsBreaks – Vericel (NASDAQ: VCEL) Shares Tick Higher; First U.S. Patient Receives MACI Implant to Treat Cartilage Defects of the Knee

Vericel (NASDAQ: VCEL) is up 4% mid-day after the company said the first patient in the United States has received the MACI® implant. MACI® is an autologous cellular scaffold product that is indicated for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. The MACI implant consists of human-derived cells (obtained from the patient's cartilage) seeded onto a resorbable type I/III collagen membrane. "We believe that the simplified MACI surgical technique, together with the MACI phase 3 clinical data demonstrating statistically significantly greater improvement in pain and function scores…

WednesdayFeb 01, 2017 1:24 pm

NetworkNewsBreaks – Helios and Matheson Analytics (NASDAQ: HMNY) Completes Beta Testing to Add Artificial Intelligence to RedZone Map App, Shares Higher

Helios and Matheson Analytics (NASDAQ: HMNY), along with its Zone Technologies subsidiary, today announced the completion of beta testing of Zone's proprietary artificial intelligence (AI) technology. The AI integration is led by Dr. E.G. Rajan, chair and founding member of HMNY and Zone's Science & Technology Development Board, who has spent over 30 years researching AI and machine learning. Zone intends to include this AI technology in its RedZone Map app, providing features designed to analyze recent crime patterns and predict criminal activity. "The incorporation of artificial intelligence into RedZone Map will transform the app's data set into the ultimate…

WednesdayFeb 01, 2017 12:32 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on February 1, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: NNSV 177.78% – News: Signs bio research agreement with Phage Consultants Co. SNBP 94.44% – News: Receives grant from NIH to study SBP-101 for the treatment of pancreatitis BRKK 26.09% – News: RefCAM used to broadcast portions of the NHL All-Star game PTCO 17.86% – News: Acquires mineral rights in Oklahoma VPRB 15.85% – News: Enters into exclusive distribution and sales agreement with Alpha-Cat MCIG 11.56% – News: Announces $200,000 investment from CEO and…

WednesdayFeb 01, 2017 11:19 am

NetworkNewsBreaks – National Waste Management Holdings, Inc. (NWMH) Acquisition Expands Presence in New York

Solid waste management company National Waste Management Holdings, Inc. (OTC: NWMH) this morning announced some of the immediate growth opportunities stemming from its December acquisition of Northeast Data Destruction and Recycling, LLC. Notably, the acquisition immediately strengthened National Waste’s market reach in upstate New York, which now extends south to the Kingston, New York, headquarters of Northeast Data Destruction and Recycling. In line with its vertically integrated business model, the company plans to implement its existing offerings, including roll-off services, at its new Kingston operation in an effort to promote sustainable market growth. Looking forward, National Waste intends to continue…

WednesdayFeb 01, 2017 11:16 am

NetworkNewsBreaks – ChineseInvestors.com (CIIX) Launches ChineseCBDoil.com Website; Featured in Interview Outlining Entry into Cannabis Industry

ChineseInvestors.com (OTCQB: CIIX) has launched a new website for its ChineseCBDoil.com subsidiary, through which CIIX is expanding into the medical marijuana industry. The site is an online retailer of hemp oil and related products, which are legal to sell and distribute within China as well as in the United States. “Our expertise in online communications with our background in media, technology, and journalism, via our http://www.Chinesefn.com website will further enhance our success,” CEO Warren Wang stated in the news release. “Our core business, the online distribution of news to the Chinese speaking population about financial markets and stocks has been…

TuesdayJan 31, 2017 2:29 pm

NetworkNewsBreaks – Ocera Therapeutics (NASDAQ: OCRX) Steady with ‘Buy’ Rating, but Lower PT Following OCR-002 Top Line Results

Maintaining a ‘Buy’ rating on Ocera Therapeutics (NASDAQ: OCRX), Aegis Capital has lowered its price target on the company’s stock to $3 from $8. Ocera yesterday reported top-line results from its exploratory STOP-HE phase 2b study of OCR-002 in hospitalized patients with hepatic encephalopathy (HE). OCR-002 missed its primary endpoint, though results show dose-dependent clinical improvement. “The patients at the higher doses (15 and 20 grams) had faster clinical improvement and greater complete response rates compared to the patients on the lowest dose (10 grams) and those on placebo. These findings will be integral in determining dose levels for future…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks